Insulin

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 265-280

  Beals, John M ^a   DeFelippis, Michael R ^a   Kovach, Paul M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051771766     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with noninsulin- dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157:1249-55.
2. Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, et al. The structure of 2Zn pig insulin crystals at 1.5 A ° resolution. Philos Trans R Soc Lond B 1988; 319:369-456.
3. Balschmidt P, Benned Hansen F, Dodson EJ, Dodson GG, Korber F. Structure of porcine insulin cocrystallized with clupeine-Z. Acta Crystallogr B 1991; B47:975-86.
4. Balschmidt P. (1996) AspB28 Insulin Crystals. United States Patent 5;547:930.
5. Bell DSH, Clements RS, Perentesis G, Roddam R, Wagenknecht L. Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med 1991; 151:2265-9.
6. Bliss M. Who discovered insulin. In: The discovery of insulin. Toronto: McClelland and Stewart Limited; 1982. p. 189-211.
7. Brackenridge B. Diabetes medicines: insulin. In:Brackenridge B, editor. Managing your diabetes. Indianapolis (Indiana, USA): Eli Lilly and Company; 1994. p. 36-50.
8. Brader ML, Dunn MF. Insulin hexamers: new conformations and applications. TIBS 1991; 16:341-5.
9. Brange J. Insulin preparations. In: Galenics of insulin. Berlin:Springer-Verlag; 1987a. p. 17-39.
10. Brange J. Production of bovine and porcine insulin. In:Galenics of Insulin. Berlin: Springer-Verlag; 1987b. p. 1-5.
11. Brange J, Havelund S, Hougaard P. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res 1992a; 9:727-34.
12. Brange J, Langkjær L, Havelund S, Vølund A. Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res 1992b; 9:715-26.
13. Brange J Langkjær L. Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. Acta Pharm Nord 1992; 4:149-58.
14. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical applications. Diabetes Care 1990; 13:923-54.
15. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988; 333:679-82.
16. Brems DN, Alter LA, Beckage MJ, Chance RE, DiMarchi RD, Green LK, et al. Altering the association properties of insulin by amino acid replacement. Prot Eng 1992; 6:527-33.
17. Brennan TV, Clarke S. Deamidation and isoasparate formation in model synthetic peptides. In Aswad DW, editor. Deamidation and isoaspartate formation in peptides and proteins. Boca Raton (Florida, USA):CRC Press; 1994. p. 65-90.
18. Cefalu WT. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004; 27:239-46.
19. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther 2004; 26:2084-91.
20. Chance RE. Bioactivity data for insulin related substances. Personal Communication. Indianapolis (Indiana, USA): Eli Lilly and Company; 1995.
21. Ciszak E, Beals JM, Baker JC, Carter ND, Frank BH, Smith GD. The role of the C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29- human insulin. Structure 1995; 3:615-22.
22. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27:2363-8.
23. Darrington RT, Anderson BD. Effects of insulin concentration and self-association on the partitioning of its A-21 cyclic anhydride intermediate to desamido insulin and covalent dimer. Pharmcol Res 1995; 12:1077-84.
24. Davis SN, Thompson CJ, Brown MD, Home PD, Alberti KGMM. A comparison of the pharmacokinetics and metabolic effects of Human Regular and NPH mixtures. Diabetes Res Clin Pract 1991; 13:107-18.
25. Deckert T. Intermediate-acting insulin preparations: NPH and Lente. Diabetes Care 1980; 3:623-6.
26. DeFelippis MR, Bakaysa DL, Bell MA, Heady MA, Li S, Pye S, et al. Preparation and characterization of a cocrystalline suspension of [LysB28, ProB29]-human insulin analogue. J Pharm Sci 1998; 87:170-6.
27. DeFelippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther 2006 (June); 8(3): 358-68.
28. Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, et al. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature 1989; 338:594-6.
29. Dodd SW, Havel HA, Kovach PM, Lakshminarayan C, Redmon MP, Sargeant CM, et al. Reversible adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electrostatic interaction. Pharmcol Res 1995; 12:60-8.
30. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005; 37:702-7.
31. Galloway JA. Chemistry and clinical use of insulin. In:Galloway JA, Potvin JH, Shuman CR, editors. Diabetes mellitus. 9th ed. Indianapolis (Indiana, USA): Lilly Research Laboratories; 1988. p. 105-33.
32. Galloway JA, Chance RE. Improving insulin therapy:achievements and challenges. Horm Metab Res 1994; 26:591-8.
33. Galloway JA, Spradlin CT, Jackson RL, Otto DC, Bechtel LD. Mixtures of intermediate-acting insulin (NPH and Lente) with regular insulin: an update. In: Skyler JS, editor. Insulin update: 1982. Princeton: Exerpta Medica; 1982. p. 111-9.
34. Goldman J, Carpenter FH. Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives. Biochemistry 1974; 13:4566-74.
35. Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I. Protamine insulinate. JAMA 1936; 106:177-80.
36. Hallas-Møller K, Jersild M, Petersen K, Schlichtkrull J. Zinc insulin preparations for single daily injection. JAMA 1952; 150:1667-71.
37. Hamaguchi T, Hashimoto Y, Miyata T, Kishikawa H, Yano T, Fukushima H, et al. Effect of mixing short and intermediate NPH insulin or Zn insulin suspension acting Human insulin on plasma free insulin levels and action profiles. J Jpn Diabet Soc 1990; 33:223-9.
38. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmcol Res 2004; 21:1498-504.
39. Heinemann L, Pfützner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001; 7:1327-51.
40. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16:332-8.
41. Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapidacting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes 1997; 105:140-4.
42. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21:800-3.
43. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basalbolus therapy. Diabetes Care 2001; 24:296-301.
44. Himmelmann A, Jendle J, Mellén A, Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26:677-82.
45. Hoffmann JA, Chance RE, Johnson MG. Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography. Protein Expr Purif 1990; 1:127-33.
46. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28),Pro(B29)]-human insulin: a rapidly-absorbed analogue of human insulin. Diabetes 1994; 43:396-402.
47. Janssen MMJ, Casteleijn S, Devillé W, Popp-Snijders C, Roach P, Heine RJ. Nighttime insulin kinetics and glycemic control in type 1 diabetic patients following administration of an intermediate-acting lispro preparation. Diabetes Care 1997; 20:1870-3.
48. Kaarsholm NC, Havelund S, Hougaard P. Ionization behavior of native and mutant insulins: pK Perturbation of B13-Glu in aggregated species. Arch Biochem Biophys 1990; 283:496-502.
49. Krayenbühl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Hosp (Kbh) 1946; 1:60-73.
50. Kroeff EP, Owen RA, Campbell EL, Johnson RD, Marks HI. Production scale purification of biosynthetic human insulin by reversed phase high performance liquid chromatography. J Chromatography 1989; 461:45-61.
51. Kurtz AB, Gray RS, Markanday S, Nabarro JDN. Circulating IgG antibody to protamine in patients treated with protamine-insulins. Diabetologia 1983; 25:322-4.
52. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMistTM System. Diabetes Metab Res Rev 2002; 18(Suppl. 1):S38-42.
53. Nell LJ, Thomas JW. Frequency and specificity of protamine antibodies in diabetic and control subjects. Diabetes 1988; 37:172-6.
54. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43:781-801.
55. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35:235-47.
56. Patton JS. Deep-lung delivery of proteins. Mod Drug Disc 1998; 1:19-28.
57. Pekar AH, Frank BH. Conformation of proinsulin. A comparison of insulin and proinsulin self-association at neutral pH. Biochemistry 1972; 11:4013-6.
58. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89:297-310.
59. Robertson KE, Glazer NB, Campbell RK. The latest developments in insulin injection devices. Diabetes Educ 2000; 26:135-52.
60. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7:167-9.
61. USP Monographs: insulin. (2006) USP 29-NF 24.
62. Vague P, Selam J-L, Skeie S, De Leeuw I, Elte JWF, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26:590-6.
63. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Diabetes Care 1997; 20:1612-4.
64. Whittingham JL, Jonassen I, Havelund S, Roberts SM, Dodson EJ, Verma CS, et al. Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins. Biochemistry 2004; 43:5987-95.
65. Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro ! Asp insulin analogues. Biochemistry 1998; 37:11516-23.
66. Yip CM, DeFelippis MR, Frank BH, Brader ML, Ward MD. Structural and morphological characterization of Ultralente insulin crystals by atomic force microscopy:evidence of hydrophobically driven assembly. Biophys J 1998; 75:1172-9.
67. Bliss M. The discovery of insulin. Toronto: McClelland and Stewart Limited; 1982.
68. Brange J. Galenics of insulin. Berlin: Springer-Verlag; 1987.
69. Galloway JA, Potvin JH, Shuman CR. Diabetes mellitus. 9th ed. Indianapolis (Indiana, USA): Lilly Research Laboratories; 1988.